Search Bar & Filters
Found 80 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.
Actively Recruiting
Researchers are comparing two chemotherapy approaches combined with standard surgery and radiation in patients newly diagnosed with intermediate-risk rhabdomyosarcoma. This phase III trial evaluates whether a higher dose chemotherapy over a shorter time performs better or differently than a lower dose chemotherapy with maintenance over a longer period. The study also examines survival rates, treatment side effects, and molecular features of the cancer. Participants are randomly assigned to one of two treatment regimens. Regimen A involves vincristine, dactinomycin, and a higher dose of cyclophosphamide given intravenously over multiple 21-day cycles, with possible surgery in week 12 and radiation during later cycles. Regimen B uses a lower cyclophosphamide dose alternating with vincristine and irinotecan, followed by 24 weeks of maintenance chemotherapy with vinorelbine and oral cyclophosphamide. Both groups undergo imaging scans and may have biopsies during the study. Throughout the trial, participants attend scheduled visits for chemotherapy administration, imaging CT, MRI, PET, blood and other sample collections, and monitoring of side effects. After treatment, follow-up visits occur every 3 months for the first year, then less frequently over 5 years. Researchers measure event-free survival, overall survival, local tumor control, treatment-related adverse events, and timely molecular biomarker reporting. Biospecimens are collected for future research and fertility preservation is assessed.
Actively Recruiting
Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.
Actively Recruiting
Researchers are evaluating the safety and long-term effectiveness of the VARIPULSE Catheter System in treating persistent atrial fibrillation PsAF, a heart rhythm disease. The study focuses on patients undergoing catheter ablation procedures involving pulmonary vein isolation PVI and superior vena cava isolation SVCI, with some also receiving posterior wall isolation PWI. Additionally, it assesses safety for those having a simultaneous left atrial appendage occlusion LAAO procedure to reduce stroke risk. Participants will receive catheter ablation treatment using the VARIPULSE Catheter System, which includes a bi-directional catheter and generator delivering pulsed field ablation. Two groups are studied one undergoing PVI and SVCI, and another receiving PVI, SVCI plus PWI. Some participants in both groups may also have a concurrent LAAO procedure using commercially available devices. Follow-up for all participants extends up to 36 months after the procedures. Throughout the study, participants will be monitored for early adverse events within about 7 days post-procedure and for occurrences of atrial tachyarrhythmia from 2 to 6 months after treatment. Quality of life changes will be evaluated at 12 months using a specific atrial fibrillation questionnaire. Researchers will also track safety and effectiveness over 3 years through regular assessments, which may include clinical visits, tests, and questionnaires to measure heart rhythm stability and stroke risk reduction.
Actively Recruiting
Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.
Actively Recruiting
Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.
Actively Recruiting
Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
1-10 of 80
1